Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement Firms Confounded By Identity Testing Waiver Process

This article was originally published in The Tan Sheet

Executive Summary

FDA says it has not received any petitions to request an exemption from the 100% supplement ingredient identity testing requirement. Food and drug attorneys say the hassle of preparing a petition for a waiver outweighs the potential benefits

Advertisement

Related Content

Industry News Roundup
Industry News Roundup
First GMP Warning Letter Reflects FDA's List Of Major Concerns
GMP Interim Final Rule Sets Bar High For 100% Testing Exemption – Experts

Topics

Advertisement
UsernamePublicRestriction

Register

PS106711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel